| Literature DB >> 34825784 |
Ji Tu1,2, Wentian Li2, Sidong Yang3,4, Pengyi Yang5,6,7, Qi Yan1, Shenyu Wang1, Kaitao Lai8,9, Xupeng Bai10, Cenhao Wu1, Wenyuan Ding4, Justin Cooper-White3,11, Ashish Diwan2,12, Cao Yang13, Huilin Yang1, Jun Zou1.
Abstract
Although degeneration of the nucleus pulposus (NP) is a major contributor to intervertebral disc degeneration (IVDD) and low back pain, the underlying molecular complexity and cellular heterogeneity remain poorly understood. Here, a comprehensive single-cell resolution transcript landscape of human NP is reported. Six novel human NP cells (NPCs) populations are identified by their distinct molecular signatures. The potential functional differences among NPC subpopulations are analyzed. Predictive transcripts, transcriptional factors, and signal pathways with respect to degeneration grades are explored. It is reported that fibroNPCs is the subpopulation for end-stage degeneration. CD90+NPCs are observed to be progenitor cells in degenerative NP tissues. NP-infiltrating immune cells comprise a previously unrecognized diversity of cell types, including granulocytic myeloid-derived suppressor cells (G-MDSCs). Integrin αM (CD11b) and oxidized low density lipoprotein receptor 1 (OLR1) as surface markers of NP-derived G-MDSCs are uncovered. The G-MDSCs are found to be enriched in mildly degenerated (grade II and III) NP tissues compared to severely degenerated (grade IV and V) NP tissues. Their immunosuppressive function and alleviation effects on NPCs' matrix degradation are revealed in vitro. Collectively, this study reveals the NPC-type complexity and phenotypic characteristics in NP, thereby providing new insights and clues for IVDD treatment.Entities:
Keywords: intervertebral disc degeneration; low back pain; nucleus pulposus; single-cell RNA sequencing
Mesh:
Year: 2021 PMID: 34825784 PMCID: PMC8787427 DOI: 10.1002/advs.202103631
Source DB: PubMed Journal: Adv Sci (Weinh) ISSN: 2198-3844 Impact factor: 16.806
Basic information and characteristics for participants
| Patient ID | Age [years] | Gender | Weight [kg] | Reason for surgery | Pfirrmann grading | CRP [mg dL−1] | WBC (109 L−1) | Lymphocyte (109 L−1) | Monocyte (109 L−1) |
|---|---|---|---|---|---|---|---|---|---|
| S1 | 63 | Male | 60 | Burst fracture | II | 0.047 | 6.46 | 2.16 | 0.64 |
| S2 | 41 | Male | 73.5 | Burst fracture | II | 0.706 | 11.37 | 2.35 | 1.02 |
| S3 | 56 | Female | 62 | Lumbar disc herniation | III | 0.079 | 7.25 | 1.63 | 0.47 |
| S4 | 65 | Female | 76 | Lumbar disc herniation | III | 0.154 | 6.78 | 2.15 | 0.54 |
| S5 | 64 | Female | 50 | Lumbar disc herniation | IV | 0.027 | 4.83 | 1.55 | 0.19 |
| S6 | 53 | Female | 60 | Lumbar disc herniation | IV | 0.184 | 5.53 | 2.28 | 0.49 |
| S7 | 54 | Male | 68 | Lumbar disc herniation | V | 0.011 | 10.79 | 3.55 | 0.83 |
| S8 | 56 | Male | 55 | Lumbar disc herniation | V | 0.022 | 5.75 | 1.86 | 0.61 |
Figure 1Identification of human NPC atlas and transcriptional changes correlated with IVDD severity. A) Graphical representation of the experimental workflow. B) UMAP visualization of human NP cells identified six different clusters after unsupervised clustering. Each dot corresponds to one single cell colored according to cell cluster. C) Heatmap revealing the scaled expression of differentially expressed genes for each cluster. D) Dot plots showing the grade distribution in each NP cell subsets. E) RT‐qPCR for the representative genes of NPC atlas in different degenerative grades discs (n = 3 with mean ± SD shown). F) Representative immunohistochemistry assay of indicated genes in NP tissues. G) Heatmap showing grade‐related transcription factors. H) Enriched signal pathways related with degeneration grades.
DEGs by comparing severe degeneration grade (Grade III and IV) to mild degeneration grade (Grade I and II)
| Upregulated genes | |||||
|---|---|---|---|---|---|
| Gene |
| avg_logFC | pct.1 | pct.2 | p_val_adj |
| INHBA | 0 | 1.542242 | 0.787 | 0.491 | 0 |
| FHL2 | 0 | 1.355454 | 0.65 | 0.274 | 0 |
| KLHL21 | 0 | 1.150942 | 0.633 | 0.334 | 0 |
| CYR61 | 0 | 1.149118 | 0.947 | 0.887 | 0 |
| HSPA1B | 0 | 1.059508 | 0.868 | 0.733 | 0 |
| NFATC2 | 0 | 1.027662 | 0.497 | 0.173 | 0 |
| HSPH1 | 0 | 0.983483 | 0.813 | 0.634 | 0 |
| CTGF | 0 | 0.979719 | 0.957 | 0.877 | 0 |
| MMP13 | 0 | 0.948365 | 0.822 | 0.626 | 0 |
| HSP90AA1 | 0 | 0.899521 | 0.964 | 0.896 | 0 |
| RTN4 | 0 | 0.759251 | 0.836 | 0.694 | 0 |
| HSPA8 | 0 | 0.650494 | 0.882 | 0.8 | 0 |
| ACTG1 | 0 | 0.627876 | 0.979 | 0.96 | 0 |
| ANXA5 | 0 | 0.608453 | 0.908 | 0.839 | 0 |
| LUM | 0 | 0.58595 | 0.984 | 0.97 | 0 |
| H3F3B | 0 | 0.496407 | 0.963 | 0.94 | 0 |
| HSPA1A | 5.2 × 10−284 | 0.735349 | 0.91 | 0.866 | 1.1 × 10−279 |
| GFPT2 | 6.9 × 10−261 | 0.734121 | 0.682 | 0.489 | 1.5 × 10−256 |
| KLF4 | 7 × 10−258 | 0.702163 | 0.905 | 0.846 | 1.5 × 10−253 |
| ATP1B1 | 6.7 × 10−252 | 0.710599 | 0.614 | 0.392 | 1.5 × 10−247 |
| PCOLCE2 | 1.2 × 10−250 | 0.563587 | 0.869 | 0.752 | 2.6 × 10−246 |
| EMP1 | 7.9 × 10−244 | 0.770794 | 0.907 | 0.84 | 1.7 × 10−239 |
| SLC39A14 | 9.2 × 10−242 | 0.606197 | 0.801 | 0.68 | 2 × 10−236 |
| HERPUD1 | 1.3 × 10−237 | 0.515521 | 0.873 | 0.801 | 2.8 × 10−233 |
| PLOD2 | 5.6 × 10−227 | 0.471544 | 0.866 | 0.805 | 1.2 × 10−222 |
| HSPB8 | 1.8 × 10−224 | 0.780165 | 0.687 | 0.502 | 4 × 10−220 |
| ZSWIM6 | 1.8 × 10−219 | 0.548961 | 0.309 | 0.088 | 3.8 × 10−215 |
| BTF3 | 3.4 × 10−219 | 0.457349 | 0.863 | 0.785 | 7.4 × 10−215 |
| ANXA1 | 2.2 × 10−216 | 0.58282 | 0.928 | 0.894 | 4.7 × 10−212 |
| ACKR3 | 4.6 × 10−215 | 0.909398 | 0.595 | 0.397 | 1 × 10−210 |
| MYADM | 1.2 × 10−214 | 0.682027 | 0.739 | 0.614 | 2.5 × 10−210 |
| ACTB | 1.6 × 10−214 | 0.357681 | 0.965 | 0.945 | 3.4 × 10−210 |
| AMOTL2 | 1.1 × 10−212 | 0.883341 | 0.388 | 0.169 | 2.5 × 10−208 |
| FOXC2 | 1.9 × 10−210 | 0.758533 | 0.43 | 0.208 | 4.2 × 10−206 |
| TXN | 1.2 × 10−201 | 0.630013 | 0.708 | 0.571 | 2.6 × 10−197 |
| UAP1 | 7.7 × 10−201 | 0.602079 | 0.708 | 0.556 | 1.7 × 10−196 |
| TM4SF1 | 4.7 × 10−200 | 0.936974 | 0.488 | 0.282 | 1 × 10−195 |
| RYBP | 1.2 × 10−199 | 0.648708 | 0.654 | 0.479 | 2.7 × 10−195 |
| FMOD | 1.1 × 10−195 | 0.535043 | 0.908 | 0.89 | 2.3 × 10−191 |
| RPL30 | 1.8 × 10−186 | 0.341223 | 0.949 | 0.941 | 3.9 × 10−182 |
| GPRC5A | 7.1 × 10−186 | 0.670452 | 0.596 | 0.403 | 1.5 × 10−181 |
| HSPD1 | 1.2 × 10−184 | 0.574874 | 0.775 | 0.666 | 2.7 × 10−180 |
| FN1 | 4.3 × 10−180 | 0.740568 | 0.968 | 0.95 | 9.4 × 10−176 |
| TMED2 | 2.4 × 10−177 | 0.583225 | 0.672 | 0.564 | 5.2 × 10−173 |
| RAN | 1.5 × 10−174 | 0.462583 | 0.799 | 0.715 | 3.3 × 10−170 |
| SERPINE2 | 2 × 10−174 | 0.721224 | 0.845 | 0.773 | 4.4 × 10−170 |
| CTNNB1 | 1.9 × 10−167 | 0.511848 | 0.66 | 0.526 | 4.2 × 10−163 |
| IL11 | 7.6 × 10−165 | 0.928692 | 0.287 | 0.1 | 1.6 × 10−160 |
| OAT | 1 × 10−163 | 0.473536 | 0.728 | 0.608 | 2.3 × 10−159 |
| CD55 | 6.3 × 10−161 | 0.717146 | 0.707 | 0.576 | 1.4 × 10−156 |
Figure 2ScRNA‐seq reveals transcriptional features of NPCs subpopulations. A) QuSAGE analysis of cell subpopulation specific differential expression colored by statistically significant normalized enrichment scores. B–E) Violin plots of steroid biosynthesis, immune response, innervation, and angiogenesis score for each cluster. F) Correlation of scRNA‐seq defined NPCs subpopulations with cell senescence. G) Heatmap showing the scaled expression of the differentially expressed genes (DEGs) for HT‐CLNP‐I and HT‐CLNP‐II subsets. H) Pseudotime trajectory axis revealing the progression of HT‐CLNP‐I and HT‐CLNP‐II.
GO Terms for NP subpopulations
| Efector NPCs GO terms | ||
|---|---|---|
| GOID | GOTerm |
|
| GO:0016126 | sterol biosynthetic process | 2.432 × 10−11 |
| GO:0006695 | cholesterol biosynthetic process | 5.795 × 10−10 |
| GO:0030198 | extracellular matrix organization | 3.136 × 10−8 |
| GO:0044281 | small molecule metabolic process | 4.528 × 10−8 |
| GO:0001558 | regulation of cell growth | 2.285 × 10−6 |
| GO:0001501 | skeletal system development | 3.133 × 10−6 |
| GO:0006694 | steroid biosynthetic process | 5.308 × 10−6 |
| GO:0008203 | cholesterol metabolic process | 9.283 × 10−6 |
| GO:0008202 | steroid metabolic process | 1.061 × 10−5 |
| GO:0006048 | UDP‐N‐acetylglucosamine biosynthetic process | 1.904 × 10−5 |
| GO:0008299 | isoprenoid biosynthetic process | 2.17 × 10−5 |
| GO:0010628 | positive regulation of gene expression | 3.007 × 10−5 |
| GO:0008285 | negative regulation of cell proliferation | 3.96 × 10−5 |
| GO:0009405 | pathogenesis | 5.295 × 10−5 |
| GO:0072593 | reactive oxygen species metabolic process | 6.08 × 10−5 |
| GO:0006629 | lipid metabolic process | 9.184 × 10−5 |
| GO:0048661 | positive regulation of smooth muscle cell proliferation | 9.297 × 10−5 |
| GO:0033173 | calcineurin‐NFAT signaling cascade | 0.0001037 |
| GO:0030199 | collagen fibril organization | 0.0001053 |
| GO:0042127 | regulation of cell proliferation | 0.0001366 |
| GO:0001525 | angiogenesis | 0.0001439 |
| GO:0014070 | response to organic cyclic compound | 0.0001497 |
| GO:0010955 | negative regulation of protein processing | 0.0001541 |
| GO:0042340 | keratan sulfate catabolic process | 0.0001541 |
| GO:0006011 | UDP‐glucose metabolic process | 0.0001563 |
| GO:0007568 | aging | 0.0001871 |
| GO:0006633 | fatty acid biosynthetic process | 0.0002058 |
| GO:0043434 | response to peptide hormone | 0.000223 |
| GO:0055114 | oxidation‐reduction process | 0.0002321 |
| GO:0005975 | carbohydrate metabolic process | 0.0003237 |
| GO:0043065 | positive regulation of apoptotic process | 0.0003622 |
| GO:0030203 | glycosaminoglycan metabolic process | 0.0003728 |
| GO:0043066 | negative regulation of apoptotic process | 0.000445 |
| GO:0003331 | positive regulation of extracellular matrix constituent secretion | 0.0004652 |
| GO:0006065 | UDP‐glucuronate biosynthetic process | 0.0004652 |
| GO:2000544 | regulation of endothelial cell chemotaxis to fibroblast growth factor | 0.0004652 |
| GO:0042542 | response to hydrogen peroxide | 0.0004732 |
| GO:0032270 | positive regulation of cellular protein metabolic process | 0.0005055 |
| GO:0006915 | apoptotic process | 0.0006357 |
| GO:0010035 | response to inorganic substance | 0.0006375 |
| GO:0008284 | positive regulation of cell proliferation | 0.0006802 |
| GO:0044255 | cellular lipid metabolic process | 0.0007222 |
| GO:0060591 | chondroblast differentiation | 0.0009226 |
| GO:1903169 | regulation of calcium ion transmembrane transport | 0.0009226 |
| GO:0006933 | negative regulation of cell adhesion involved in substrate‐bound cell migration | 0.0009226 |
| GO:0051387 | negative regulation of neurotrophin TRK receptor signaling pathway | 0.0009226 |
| GO:0009314 | response to radiation | 0.0009242 |
| GO:0060291 | long‐term synaptic potentiation | 0.0010297 |
| GO:0045444 | fat cell differentiation | 0.0013192 |
| GO:0031394 | positive regulation of prostaglandin biosynthetic process | 0.001525 |
Comparison of HT‐CLNPs‐I and HT‐CLNPs‐II
| HT‐CLNPs‐I GO terms | ||
|---|---|---|
| GOID | GOTerm |
|
| GO:0006048 | UDP‐N‐acetylglucosamine biosynthetic process | 3.524 × 10−7 |
| GO:0012501 | programmed cell death | 1.952 × 10−6 |
| GO:0008285 | negative regulation of cell proliferation | 2.502 × 10−6 |
| GO:0042026 | protein refolding | 3.032 × 10−6 |
| GO:0010467 | gene expression | 1.394 × 10−5 |
| GO:0043066 | negative regulation of apoptotic process | 1.964 × 10−5 |
| GO:0031397 | negative regulation of protein ubiquitination | 2.025 × 10−5 |
| GO:0010941 | regulation of cell death | 2.151 × 10−5 |
| GO:0007596 | blood coagulation | 2.385 × 10−5 |
| GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway | 4.689 × 10−5 |
| GO:0045648 | positive regulation of erythrocyte differentiation | 4.689 × 10−5 |
| GO:0002042 | cell migration involved in sprouting angiogenesis | 6.276 × 10−5 |
| GO:1900034 | regulation of cellular response to heat | 7.543 × 10−5 |
| GO:0006047 | UDP‐N‐acetylglucosamine metabolic process | 8.473 × 10−5 |
| GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 9.284 × 10−5 |
| GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 0.0001026 |
| GO:0006928 | cellular component movement | 0.0001158 |
| GO:0006915 | apoptotic process | 0.0001216 |
| GO:0034605 | cellular response to heat | 0.0001572 |
| GO:0007623 | circadian rhythm | 0.0001957 |
| GO:0032092 | positive regulation of protein binding | 0.0002012 |
| GO:0042267 | natural killer cell mediated cytotoxicity | 0.0002278 |
| GO:0034629 | cellular protein complex localization | 0.0002315 |
| GO:0033173 | calcineurin‐NFAT signaling cascade | 0.0002315 |
| GO:0045893 | positive regulation of transcription, DNA‐templated | 0.0002562 |
| GO:0007264 | small GTPase mediated signal transduction | 0.0002668 |
| GO:0006986 | response to unfolded protein | 0.0003037 |
| GO:0032060 | bleb assembly | 0.000343 |
| GO:0006357 | regulation of transcription from RNA polymerase II promoter | 0.0003793 |
| GO:0097193 | intrinsic apoptotic signaling pathway | 0.0004046 |
| GO:0006367 | transcription initiation from RNA polymerase II promoter | 0.0004339 |
| GO:0050821 | protein stabilization | 0.0004345 |
| GO:0010628 | positive regulation of gene expression | 0.0004551 |
| GO:0061045 | negative regulation of wound healing | 0.0004841 |
| GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 0.000569 |
| GO:0051085 | chaperone mediated protein folding requiring cofactor | 0.0006576 |
| GO:0006366 | transcription from RNA polymerase II promoter | 0.0006606 |
| GO:0045597 | positive regulation of cell differentiation | 0.0007432 |
| GO:0060128 | corticotropin hormone secreting cell differentiation | 0.0007994 |
| GO:0070370 | cellular heat acclimation | 0.0007994 |
| GO:2000544 | regulation of endothelial cell chemotaxis to fibroblast growth factor | 0.0007994 |
| GO:0043123 | positive regulation of I‐kappaB kinase/NF‐kappaB signaling | 0.0008046 |
| GO:0033138 | positive regulation of peptidyl‐serine phosphorylation | 0.0010132 |
| GO:0060129 | thyroid‐stimulating hormone‐secreting cell differentiation | 0.0015814 |
| GO:0060591 | chondroblast differentiation | 0.0015814 |
| GO:0010664 | negative regulation of striated muscle cell apoptotic process | 0.0015814 |
| GO:0022614 | membrane to membrane docking | 0.0015814 |
| GO:0015936 | coenzyme A metabolic process | 0.0015814 |
| GO:0070434 | positive regulation of nucleotide‐binding oligomerization domain containing 2 signaling pathway | 0.0015814 |
| GO:0045765 | regulation of angiogenesis | 0.0015841 |
Figure 3CD90+NPCs is the progenitor within FibroNPCs, the end‐stage subpopulation. A) Plot of the cytoTRACE pseudotime order for the NP subpopulations. The value of cytoTRACE represents the predicted order. B) Visualization for dynamic velocities projected into the UMAP‐based embedding. C) The expression of CD90, CD44, CD73, and CD29 in NPCs, the red box represents the region of fibroNPCs on UMAP. D) Histogram to evaluate the relative expression of CD90 after cell sorting. E) Left: oil red staining for CD90+ NPC‐induced adipogenic differentiation, respectively (n = 3). Scale bar, 100 µm. Right: alizarin red staining for CD90+ NPC‐induced osteogenic differentiation (n = 3). Scale bar, 100 µm. F) RT‐qPCR of fibroNPCs phenotype mRNA levels between CD90+/− NPCs. (n = 3 with mean ± SD shown, *P < 0.05, **P < 0.005). G) RT‐qPCR of adhesion NPCs phenotype at different time points after cultured CD90+NPCs in chondrogenesis induced medium (n = 3 with mean ± SD shown). H) Safranin O staining of CD90+NPCs from mild (grade II and III) or severely (grade IV and V) degenerative individuals after culturing in chondrogenesis medium for 21 d. I) Correlation of scRNA‐seq defined NPC subpopulations with cell death and inflammasome. J) Western blot analysis with representative blots including Bax, Bcl‐2m NLRP3 levels in the CD90+/− NPCs. Densitometric analysis is shown as mean ± SD, n = 3; *P < 0.05, **P < 0.005. K) Immunofluorescence (IF) visualization of CD90 (red) and nuclei (blue) in degenerative disc tissues induced in rats.
Figure 4Identification of NP‐derived G‐MDSCs. A) Uniform manifold approximation and projection (UMAP) visualization showing immune cells inside NP tissues. B) Heatmap showing the typically expressed genes in each cell type. C) Dot plot showing scaled expression of selected signature genes for GMP, G‐MDSCs, and neutrophils, by average expression of each gene in each cluster scaled across all clusters. Dot size represents the percentage of cells in each cluster with more than one read of the corresponding gene. D) Monocle method reconstructed pseudospace trajectory for GMP, G‐MDSC, and neutrophils. E) FACS isolation for CD45+ CD11b+OLR+ cells from mild/severe degenerative NP tisues. F) Safranin O/Fast Green staining of the intervertebral discs sham and experimental rats. Scale bar, 1 mm in left and 100 µm in right. G) Merged immunofluorescence staining of DAPI, CD11b, OLR1 in the intervertebral discs of sham and experimental rat. Scale bar, 1 mm in merge images and 100 µm in others.
Figure 5Validation of functions of NP‐derived G‐MDSCs. A) Schematic workflow of the experimental strategy. B) FACS isolation for CD45+ CD11b+OLR+CD24+ and CD24− cells. C) T cell suppression analysis NP‐derived G‐MDSC identification. N = 3, *P < 0.05, **P < 0.005, ***P <0 .001. D,E) CD11b+OLR+CD24+ show increased reactive oxygen species (ROS) formation compared to CD24− cells. Rosup treated cells were used as positive control. N = 3, *P < 0.05, **P < 0.005. F) RT‐qPCR of degeneration related genes, aggrecan, collagen II, ADAMTS4,5, and MMP13 in untreated, IL‐1b+G‐MDSCs, and IL‐1b alone NPC groups. N = 3, *P < 0.05, **P < 0.005, ***P < 0.001. G) Western blot analysis with representative blots including aggrecan and MMP13 in untreated, IL‐1b+G‐MDSCs, and IL‐1b alone NPC groups. N = 3, *P < 0.05, **P < 0.005, ***P < 0.001.
Figure 6Predicted immune‐NPCs regulatory network in IVDD. A) Heatmap showing the number of potential ligand–receptor pairs between cell groups. B) Bubble plots showing ligand–receptor pairs of immunomodulation, growth factors, angiogenesis, and adhesion between NPCs and other cell groups. C) Predicted regulatory network centered on NPCs.